Abstract 6062
Background
A standardized evaluation approach in oncology is essential to optimize treatment and management of patients. In particular, a medical software designed to provide standard metrics and reports may help the communication among health care professionals, facilitating the decision process. To this aim, a large survey study was conducted across the United Kingdom (UK), Spain (ES) and Italy (IT) exploring existing unmet needs and questioning the way oncological data is tracked in daily routine practice with the aim of offering some ideas for improvement.
Methods
Physicians were enrolled by an independent Market Research Company according to diiferent inclusion criteria: a) 2-35 years in practice; b) ≥50% of practice time in direct patient care; c) involvement in making treatment decisions ; d) involvement in ordering and reviewing tumour assessment reports; e) to be an investigator or author of an oncology clinical trial in the past 5 years.The study was conducted in November-December, 2018.
Results
A total number of 270 physicians (medical oncologists: n = 180, radio-oncologists: n = 90) participated (UK/100, ES/95, IT/75). The vast majority of physicians use Response Evaluation Criteria in Solid Tumors (RECIST) criteria in their daily practice (86%). Guidelines for response criteria for use in trials testing immunotherapeutics (iRECIST) and modified RECIST (mRECIST) are also used by between third and a quarter of physicians. Of note, almost half of the physicians indicated that there is a low level of data management in oncology and 2 out of 3 agree that this negatively impacts therapeutic decisions. Over a third of ES physicians believe that there is a low level of data management in oncology and a similar proportion in IT and ES report that it is impacting therapeutic decision making.
Conclusions
Only a third of physicians view their current reporting systems as adequate. All participants agree that any reporting system is in need of a common shared template for radiologists and oncologists. Thus, physicians identify a lack of consistency in diagnostic assessments and delays in receiving the reports as key unmet needs in tumor reporting systems –indicating the need for a streamlined system.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Wehealth Digital Medicine.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract
4758 - A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN); A Result of Dose Escalation Cohort
Presenter: Nuttapong Ngamphaiboon
Session: Poster Display session 3
Resources:
Abstract